Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications. In a 7-center Scandinavian double-blind placebo-controlled study of 179 patients with intermittent claudication, the effect of the serotonin antagonist ketanserin was evaluated on walking distance, brachial and ankle blood pressure, and symptoms. For all centers together, pain-free walking distance was significantly increased after 6 months with both ketanserin (+65% 71 patients) and placebo (+42%